TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $86 from $73 and keeps a Buy rating on the shares. The firm updated it mdoel following Q4 results as they believe the copmany made solid prgress during the quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments
- Promising Developments in Ultragenyx Pharmaceuticals Drive Ed Arce’s Buy Rating
- Ultragenyx Pharmaceutical Reports Strong 2024 Growth
- Ultragenyx Pharmaceutical’s Strong Sales and Promising Pipeline Support Buy Rating
- Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)